Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims ...

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing ...

Choice Institutional Equities has reiterated its positive stance on Glenmark Pharma following a major licensing deal between ...

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark Pharma's licensing deal with AbbVie will make it cash positive, improving its financial position and liquidity, according to S&P.

A warning letter is a serious communication from the USFDA that signifies a potential risk to public health or safety due to ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 2235, up 0.4% on the day as on 12:44 IST on the NSE. The stock is up 58.13% in last one year as compared to a 1.63% gain in NIFTY and a 8.9% gain in the ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Glenmark Pharmaceuticals share price surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...

Motilal Oswal said the deal validates several aspects of Glenmark Pharma such as the strength of IGI's BEAT protein platform ...

Glenmark Pharma share price today: Shares of Glenmark Pharma surged 10 per cent, recording a 52-week high of ₹2,094.40 on ...